Ten medications accounted for nearly one-third of 340B program-covered outpatient drugs in 2024, according to a Dec. 11 report.
The Health Resources and Services Administration, an HHS agency, reported that 340B covered entities purchased $81.4 billion in outpatient drugs through the 340B program in 2024. Disproportionate share hospitals spent about $64.13 billion, children’s hospitals $2.37 billion, critical access hospitals $1.19 billion, sole community hospitals $549 million, and freestanding cancer centers $602 million.
About 31% of the $81.4 billion was spent on 10 medications, according to the report.
The brand names of the 10 drugs with the highest expenditures in the 340B program last year were:
1. Keytruda (oncology) — $8.16 billion
2. Biktarvy (HIV) — $4.2 billion
3. Darzalex Faspro (oncology) — $2.46 billion
4. Opdivo (oncology) — $2.15 billion
5. Trikafta (cystic fibrosis) — $2.07 billion
6. Ocrevus (multiple sclerosis) — $1.97 billion
7. Descovy (HIV) — $1.18 billion
8. Stelara (immunology) — $1.11 billion
9. Imfinzi (oncology) — $1.09 billion
10. Entyvio (immunology) — $968 million
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
